Biotech Series B Investors & VC Firms
724 firms in this list, with a median first check of $500K. 165 of them lead rounds. Generated from verified public data and updated continuously.
A-Level Capital
BaltimorePre-Seed–Series B$40K – $100K
40 people
FoodLabs
BerlinPre-Seed–Series B
23 people
Asahi Kasei Corporate Venture Capital
Menlo ParkPre-Seed–Late Stage$200K – $5M
25 people
Keio Innovation Initiative
TokyoSeed–Growth
22 people
iGlobe Partners
SingaporeSeed–Growth$600K – $6M
23 people
Rho Ventures
New YorkPre-Seed–Growth$2M – $15M
11 people
Ysios Capital
BarcelonaSeed–Growth$5.4M – $21.6M
26 people
Two Bear Capital
WhitefishPre-Seed–Series B$3M – $10M
33 people
Innovation Industries
AmsterdamSeed–Growth$2.2M – $54M
25 people
SODENA
PamplonaSeed–Series B$108K
41 people
Ahren Innovation Capital
Cambridge, CambridgeshirePre-Seed–Growth
29 people
Argonautic Ventures
New YorkPre-Seed–Growth$5M
11 people
Safar Partners
CambridgePre-Seed–Series C
17 people
Karista
ParisPre-Seed–Growth$324K – $5.4M
12 people
Agent Capital
WalthamSeed–Late Stage
24 people
McWin Capital Partners
LondonSeries B–Growth
32 people
Antler Australia
SydneyPre-Seed–Series C$3M – $10M
17 people
Lumira Ventures
TorontoSeed–Growth$1M – $10M
17 people
iSelect Fund
St. LouisSeed–Series B$250K – $2M
10 people
venBio Partners
San FranciscoSeed–Series C
10 people
Kinnevik
StockholmSeed–Growth
20 people
SAV (Scale Asia Ventures)
Palo AltoSeed–Series B
16 people
Invest-NL
AmsterdamSeries A–Growth
23 people
Signal Peak Ventures
Salt Lake CityPre-Seed–Series B$250K – $5M
15 people
Related lists
Series B Investors & VC Firms (2951)Biotech Investors & VC Firms (2483)Biotech Seed Investors & VC Firms (2027)Series B Investors & VC Firms in North America (1738)Biotech Series A Investors & VC Firms (1627)Biotech Investors & VC Firms in North America (1601)Series B Investors & VC Firms in United States (1573)Biotech Investors & VC Firms in United States (1450)SaaS Series B Investors & VC Firms (1075)Series B Investors & VC Firms in Europe (1073)
Data sourced from public filings and firms' own websites — see our methodology.














































































































